Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease
Identifieur interne : 001169 ( Main/Exploration ); précédent : 001168; suivant : 001170Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease
Auteurs : Obering [États-Unis] ; Chen ; Swope [États-Unis]Source :
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy [ 0277-0008 ] ; 2006-06.
English descriptors
- KwdEn :
Abstract
As Parkinson's disease progresses, fluctuations between akinesia, or hypomobility (“off” times), and mobility (“on” times) increase in frequency despite optimized pharmacotherapy. Motor fluctuations include predictable shortening of therapeutic effects, nocturnal or early morning akinesia, random hypomobility, and delayed mobility (variable responses to individual doses of drugs). Current oral antiparkinson drugs are inadequate for rapid and consistent relief of symptoms during hypomobility. Apomorphine, an injectable dopamine agonist recently introduced in the United States, is indicated for the management of hypomobility associated with advanced Parkinson's disease. Subcutaneous apomorphine is effective for rapid and consistent rescue from hypomobility, with a magnitude of motor improvement similar to that of levodopa. The effect begins within 20 minutes after dosing and lasts approximately 100 minutes. Therapeutic rescue doses are 2–6 mg, and patients typically require approximately three rescue doses/day. Apomorphine is associated with a clinically significant potential to cause nausea and orthostatic hypotension. These potential effects can be managed with antiemetic prophylaxis and appropriate determination of the therapeutic rescue dose.
Url:
DOI: 10.1592/phco.26.6.840
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease</title><author><name sortKey="Obering" sort="Obering" uniqKey="Obering" last="Obering">Obering</name></author><author><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name></author><author><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:94F3D4FBB0BFBFE439638C6D7CF33E998E485221</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1592/phco.26.6.840</idno><idno type="url">https://api.istex.fr/document/94F3D4FBB0BFBFE439638C6D7CF33E998E485221/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002919</idno><idno type="wicri:Area/Main/Curation">002569</idno><idno type="wicri:Area/Main/Exploration">001169</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease</title><author><name sortKey="Obering" sort="Obering" uniqKey="Obering" last="Obering">Obering</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Missouri (État)</region></placeName><wicri:cityArea>School of Pharmacy, University of Missouri‐Kansas City, and the Department of Pharmacy, Kansas City Veterans Affairs Medical Center, Kansas City</wicri:cityArea></affiliation></author><author><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name><affiliation><wicri:noCountry code="no comma">School of Pharmacy</wicri:noCountry></affiliation></author><author><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Neurology, Movement Disorders Center (Drs. Chen and Swope), Loma Linda University, Loma Linda</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy</title><idno type="ISSN">0277-0008</idno><idno type="eISSN">1875-9114</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2006-06">2006-06</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="840">840</biblScope><biblScope unit="page" to="852">852</biblScope></imprint><idno type="ISSN">0277-0008</idno></series><idno type="istex">94F3D4FBB0BFBFE439638C6D7CF33E998E485221</idno><idno type="DOI">10.1592/phco.26.6.840</idno><idno type="ArticleID">PHAR1454</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0277-0008</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>apomorphine</term><term>dose failure</term><term>hypomobility</term><term>levodopa</term><term>mobility</term><term>motor fluctuations</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">As Parkinson's disease progresses, fluctuations between akinesia, or hypomobility (“off” times), and mobility (“on” times) increase in frequency despite optimized pharmacotherapy. Motor fluctuations include predictable shortening of therapeutic effects, nocturnal or early morning akinesia, random hypomobility, and delayed mobility (variable responses to individual doses of drugs). Current oral antiparkinson drugs are inadequate for rapid and consistent relief of symptoms during hypomobility. Apomorphine, an injectable dopamine agonist recently introduced in the United States, is indicated for the management of hypomobility associated with advanced Parkinson's disease. Subcutaneous apomorphine is effective for rapid and consistent rescue from hypomobility, with a magnitude of motor improvement similar to that of levodopa. The effect begins within 20 minutes after dosing and lasts approximately 100 minutes. Therapeutic rescue doses are 2–6 mg, and patients typically require approximately three rescue doses/day. Apomorphine is associated with a clinically significant potential to cause nausea and orthostatic hypotension. These potential effects can be managed with antiemetic prophylaxis and appropriate determination of the therapeutic rescue dose.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Missouri (État)</li></region></list><tree><noCountry><name sortKey="Chen" sort="Chen" uniqKey="Chen" last="Chen">Chen</name></noCountry><country name="États-Unis"><region name="Missouri (État)"><name sortKey="Obering" sort="Obering" uniqKey="Obering" last="Obering">Obering</name></region><name sortKey="Swope" sort="Swope" uniqKey="Swope" last="Swope">Swope</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001169 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001169 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:94F3D4FBB0BFBFE439638C6D7CF33E998E485221
|texte= Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |